JT Launches New "Mevius" Cigarette Product, Set for Nationwide Release in January 2025

Dec.05.2024
JT Launches New "Mevius" Cigarette Product, Set for Nationwide Release in January 2025
JT has announced the launch of a new product under its "Mevius" brand, the "Mevius Strong One 100's," priced at $4. The new product will be available in convenience stores and tobacco specialty shops nationwide starting January 20, 2025.

On December 4th, Japan Tobacco (JT) announced the launch of a new product under its cigarette brand "Mevius" called "Mevius Strong One 100's", priced at 580 yen (including tax) (4 USD). The new product is expected to be available for purchase at convenience stores and tobacco specialty shops nationwide starting from January 20, 2025.


The company stated that the launch of this new product is in response to consumer demand for a cigarette with stronger suction power of 1mg. They hope that by releasing "Mevius Strong One 100's", they can meet the diverse needs of their customers.


We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

Alan Zhao: In the Post-“Absolute Resolve” Era: Speculating on U.S.-Referenced Regulatory Alignment and the Restructuring of Order in South America’s Novel Tobacco Market
Alan Zhao: In the Post-“Absolute Resolve” Era: Speculating on U.S.-Referenced Regulatory Alignment and the Restructuring of Order in South America’s Novel Tobacco Market
Alan Zhao analyzes post-Operation Absolute Resolve geopolitics and the rise of “U.S.-referenced regulatory alignment” in South America’s novel tobacco market as U.S. influence grows. Using regulatory reliance, digitalized enforcement, and industrial shifts, he assesses how rule redesign may alter market access, competition, and supply chains, asking how firms can find durable certainty as order is rewritten.
Jan.06 by 2Firsts Perspectives
Jordan Reduces HTP and Vape Tax Burden as National Smoking Rate Hits 51.6%
Jordan Reduces HTP and Vape Tax Burden as National Smoking Rate Hits 51.6%
Jordan has published amendments to its special tax system reducing taxes on heated tobacco products, electronic cigarettes and e-liquids, with some reductions reaching 50%. Under the revised rules, taxes on devices and liquids have been lowered, prompting concern among medical and parliamentary circles. The government has not issued an official explanation for the move.
Dec.24 by 2FIRSTS.ai
Alcohol, tobacco and cannabis use among Spanish students aged 14–18 hits historic lows
Alcohol, tobacco and cannabis use among Spanish students aged 14–18 hits historic lows
Spain’s 2025 Survey on Drug Use in Secondary Education (ESTUDES), presented by the Ministry of Health, reports historic lows in alcohol, tobacco and cannabis consumption among students aged 14 to 18. The survey shows past-30-day drinking fell from 56.6% in 2023 to 51% in 2025, tobacco use from 21.0% to 15.5%, and cannabis use from 15.5% to 11.6%.
Feb.09 by 2FIRSTS.ai
Hampshire Trading Standards Seizes £138,000 Worth of Illegal Vapes and Tobacco in 2025
Hampshire Trading Standards Seizes £138,000 Worth of Illegal Vapes and Tobacco in 2025
According to Hampshire County Council, its Trading Standards team confiscated 116,000 illegal vape and tobacco products in 2025, worth an estimated £138,000 — a record annual haul.
Feb.02 by 2FIRSTS.ai
PMI reshuffles U.S. footprint: Swedish Match to shut Richmond office in April; most staff may be relocated
PMI reshuffles U.S. footprint: Swedish Match to shut Richmond office in April; most staff may be relocated
Swedish Match, a unit of Philip Morris International (PMI), will close its office in Richmond, Virginia, in April 2026 and eliminate 135 positions. PMI said the move is tied to adjustments in its U.S. operating footprint.
Feb.03
Philip Morris International: Over $20 Billion Invested in the U.S. Since 2022; IQOS ILUMA to Launch Pending FDA Authorization
Philip Morris International: Over $20 Billion Invested in the U.S. Since 2022; IQOS ILUMA to Launch Pending FDA Authorization
Philip Morris International (PMI) said its U.S.-related investments have topped $20 billion since 2022, when it entered the U.S. market through its roughly $19 billion acquisition of Swedish Match. The company also said it plans to launch its heated tobacco product IQOS ILUMA in the United States pending authorization from the U.S. Food and Drug Administration (FDA).
Jan.16 by 2FIRSTS.ai